Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Wuhan Easy Diagnosis Biomedicine Co Ltd
Additional Paid In Capital
Wuhan Easy Diagnosis Biomedicine Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
|
Additional Paid In Capital
¥818.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Additional Paid In Capital
¥702.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Additional Paid In Capital
¥1.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
61%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Additional Paid In Capital
¥6.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Additional Paid In Capital
¥1.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
16%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Additional Paid In Capital
¥13.9B
|
CAGR 3-Years
63%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Wuhan Easy Diagnosis Biomedicine Co Ltd
Glance View
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is engaged in the manufacturing and selling of the Diagnosis Biomedicine related equipment. The company is headquartered in Wuhan, Hubei and currently employs 1,144 full-time employees. The company went IPO on 2018-07-10. The firm's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The firm's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
See Also
What is Wuhan Easy Diagnosis Biomedicine Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
818.1m
CNY
Based on the financial report for Sep 30, 2025, Wuhan Easy Diagnosis Biomedicine Co Ltd's Additional Paid In Capital amounts to 818.1m CNY.
What is Wuhan Easy Diagnosis Biomedicine Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
17%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Wuhan Easy Diagnosis Biomedicine Co Ltd have been -2% over the past three years , 17% over the past five years .
